Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Jun;45(2):111-4.
doi: 10.3347/kjp.2007.45.2.111.

Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand

Srivicha Krudsood  1 , Noppadon Tangpukdee, Sant Muangnoicharoen, Vipa Thanachartwet, Nutthanej Luplertlop, Siripan Srivilairit, Polrat Wilairatana, Shigeyuki Kano, Pascal Ringwald, Sornchai Looareesuwan
Affiliations
Randomized Controlled Trial

Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand

Srivicha Krudsood et al. Korean J Parasitol. 2007 Jun.

Abstract

Chloroquine remains the drug of choice for the treatment of vivax malaria in Thailand. Mixed infections of falciparum and vivax malaria are also common in South-East Asia. Laboratory confirmation of malaria species is not generally available. This study aimed to find alternative regimens for treating both malaria species by using falciparum antimalarial drugs. From June 2004 to May 2005, 98 patients with Plasmodium vivax were randomly treated with either artemether-lumefantrine (n = 47) or chloroquine (n = 51). Both treatments were followed by 15 mg of primaquine over 14 days. Adverse events and clinical and parasitological outcomes were recorded and revealed similar in both groups. The cure rate was 97.4% for the artemether-lumefantrine treated group and 100% for the chloroquine treated group. We concluded that the combination of artemether-lumefantrine and primaquine was well tolerated, as effective as chloroquine and primaquine, and can be an alternative regimen for treatment of vivax malaria especially in the event that a mixed infection of falciparum and vivax malaria could not be ruled out.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percentage of parasite reduction after treatment.
See this image and copyright information in PMC

References

    1. Bair KJ. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother. 2004;48:4075–4083. - PMC - PubMed
    1. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recrudescence and whole blood chloroquine level. Am J Trop Med Hyg. 1997;5:621–626. - PubMed
    1. Hamedi Y, Safa O, Zare S, Tan-ariya P, Kojima S, Looareesuwan S. Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand. Southeast Asian J Trop Med Public Health. 2004;35:570–574. - PubMed
    1. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Aewiff S, Denis MB, Lim C, Socheat D. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol. 2004;57:253–262. - PMC - PubMed
    1. Looareesuwan S, White NJ, Chittamas S, Bunnag D, Harinasuta T. High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet. 1987;2:1052–1054. - PubMed

Publication types

MeSH terms

LinkOut - more resources